ASP 8273

Drug Profile

ASP 8273

Alternative Names: ASP8273

Latest Information Update: 18 May 2017

Price : $50

At a glance

  • Originator Astellas Pharma
  • Class Antineoplastics; Piperazines; Piperidines; Pyrazines; Pyrrolidines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 10 May 2017 Discontinued - Phase-III for Non-small cell lung cancer (First-line therapy, Late-stage disease) in USA, Australia, Belgium, Canada, Chile, France, Germany, Hungary, Italy, Japan, Malaysia, the Netherlands, Portugal, Romania, Singapore, South Korea, Spain, Taiwan, Ukraine and the UK (PO)
  • 10 May 2017 Astellas Pharma terminates the phase III SOLAR trial in Non-small cell lung cancer in USA, Australia, Belgium, Canada, Chile, France, Germany, Hungary, Italy, Japan, Malaysia, the Netherlands, Portugal, Romania, Singapore, South Korea, Spain, Taiwan, Ukraine and the UK (NCT02588261)
  • 28 Feb 2017 Astellas initiates enrolment in a phase I trial for Non small cell lung cancer (PO) in USA (NCT03082300)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top